Roscovitine targets, protein kinases and pyridoxal kinase
about
The basal transcription machinery as a target for cancer therapyEqual opportunity for low-degree network nodes: a PageRank-based method for protein target identification in metabolic graphsCrystal Structure of human pyridoxal kinase: structural basis of M(+) and M(2+) activationThe selectivity of protein kinase inhibitors: a further updateRoscovitine in cancer and other diseasesTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsScreening marine resources to find novel chemical inhibitors of disease-relevant protein kinasesCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsChemical, genetic and structural assessment of pyridoxal kinase as a drug target in the African trypanosomeCrystal Structures of Human Pyridoxal Kinase in Complex with the Neurotoxins, Ginkgotoxin and Theophylline: Insights into Pyridoxal Kinase InhibitionAffinity-Based Probes Based on Type II Kinase InhibitorsLocomotor conditioning by amphetamine requires cyclin-dependent kinase 5 signaling in the nucleus accumbensDelayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke modelsBinding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurementsCDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction pointDNA-PK target identification reveals novel links between DNA repair signaling and cytoskeletal regulationCdk-mediated phosphorylation of the Kvβ2 auxiliary subunit regulates Kv1 channel axonal targetingStimulation of the epithelial sodium channel (ENaC) by cAMP involves putative ERK phosphorylation sites in the C termini of the channel's beta- and gamma-subunitCross-talk of GATA-1 and P-TEFb in megakaryocyte differentiation.Small molecule screen for compounds that affect vascular development in the zebrafish retinaATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change.Bioactive Metabolites from the Deep Subseafloor Fungus Oidiodendron griseum UBOCC-A-114129.Phosphorylation of steroidogenic factor 1 is mediated by cyclin-dependent kinase 7CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements.First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors.Protein kinase affinity reagents based on a 5-aminoindazole scaffoldChk1 promotes replication fork progression by controlling replication initiation.Chemical proteomics: terra incognita for novel drug target profiling.Chemistry-based functional proteomics for drug target deconvolution.Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cellsStudies on quantitative phosphopeptide analysis by matrix-assisted laser desorption/ionization mass spectrometry without label, chromatography or calibration curvesCell cycle proliferation decisions: the impact of single cell analyses.Identification of a novel cyclin required for the intrinsic apoptosis pathway in lymphoid cells.Target identification and mechanism of action in chemical biology and drug discovery.Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismPharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice.The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - RoscovitineRegulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus.
P2860
Q21246017-BAE8000D-D63D-4358-A1E4-BCBF6800BEB0Q21559702-82C1257B-CDD6-4A49-B3CE-AC26DECE5B51Q24338870-FC71BCFE-DF08-4F19-9260-F091904684B3Q24654622-87EDBB61-0E0A-422B-A484-FFB56C83AD88Q26799874-0A6AC089-09A4-417B-83A9-BF18D51284BAQ26827580-7B616F0C-464D-45A5-9FF5-6593886A697CQ27026168-90CBA0C5-C199-43B5-84AD-39FEEB943E41Q27670943-F11E2C35-6A84-44FA-89A4-26AC67A26BB7Q27671077-F6412757-F014-4687-84C6-26326B467B37Q27671443-4D8E9727-2B56-40BC-9208-B1C5D6B640DCQ27674665-0DEA3790-C424-4EAB-98DD-FA898F65E6D4Q28390747-185050CF-0F21-423C-BF69-6FEFADF9B413Q28475093-1EADDBD5-052E-4618-AE8D-82F08AC482E7Q28475132-BD58F0CB-639A-4583-A158-CAC68F16A6A9Q28533417-2451E869-A701-405D-A211-A493593D4FEEQ28535408-9202674A-5E9C-4A90-AA93-CCF4A61DF79AQ28577143-3A134DF4-9B51-45C9-A2E6-10D3C544DE8FQ28577168-AE915081-B3F3-446E-BE25-1BE4ECC33CDFQ30437637-8946E889-736C-474D-AFC2-7505A4A34E74Q30491582-12BDCD25-D6A3-4470-933F-47262C7E1C24Q33356400-521786C6-CDDA-4A74-A4AF-82E6FD6F2068Q33612242-365F6757-4F77-4543-9F70-213FDDF65899Q33643318-4F609720-ED44-4930-B567-C2BC839AB95DQ33864755-F1D62465-21B8-4E8B-9F7D-CB1FDB64047DQ33927283-9BDEDC39-FE01-417C-95A2-EABDC93D7B15Q33935146-D61E8D3A-CF09-43A3-A814-CFD5B569EFB8Q34069099-C8203E5D-3056-4FC4-9E0A-DEA7FB4764C3Q34136566-C129BB43-CEEE-44E7-A707-997B9542749AQ34284580-8B6BF176-1CB3-4993-B72C-69C7A805C802Q34342905-916036EC-9DB3-4052-918D-7684D4D03A36Q34362853-2953DA17-04C9-4EB5-8A9D-80A40C3B3450Q34477921-C84D926E-A40B-4FE6-8888-EF2115986CB4Q34540440-F3F1487C-0A24-43E6-B79A-CB6894CC62BDQ34598872-AA8D45DB-A68C-443D-B442-79863A86049DQ34626974-8B35E885-0170-407F-AC20-102FAFAB95B9Q34805533-83EF7F5F-DC1B-486C-9FCB-CB9A7CD55778Q34954019-BF576147-700E-4E17-9E15-4E798191BC94Q35002296-85B92730-356E-43BC-8C02-9838488E5796Q35062145-EBE4E1B0-5071-4B35-8C61-276DF3F00180Q35072662-EBCA4902-58AC-400B-A733-A23B36CF6B48
P2860
Roscovitine targets, protein kinases and pyridoxal kinase
description
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2005
@ast
im September 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2005/09/02)
@sk
vědecký článek publikovaný v roce 2005
@cs
wetenschappelijk artikel (gepubliceerd op 2005/09/02)
@nl
наукова стаття, опублікована у вересні 2005
@uk
name
Roscovitine targets, protein kinases and pyridoxal kinase
@ast
Roscovitine targets, protein kinases and pyridoxal kinase
@en
Roscovitine targets, protein kinases and pyridoxal kinase
@nl
type
label
Roscovitine targets, protein kinases and pyridoxal kinase
@ast
Roscovitine targets, protein kinases and pyridoxal kinase
@en
Roscovitine targets, protein kinases and pyridoxal kinase
@nl
prefLabel
Roscovitine targets, protein kinases and pyridoxal kinase
@ast
Roscovitine targets, protein kinases and pyridoxal kinase
@en
Roscovitine targets, protein kinases and pyridoxal kinase
@nl
P2093
P50
P3181
P356
P1476
Roscovitine targets, protein kinases and pyridoxal kinase
@en
P2093
Andrea S. Lerman
Blandine Baratte
Christoph Schächtele
Dong-Cai Liang
Flavio Meggio
Frank Totzke
Hervé Galons
Jean-Francois Dierick
Jens Reinhardt
Laurent Meijer
P304
31208–31219
P3181
P356
10.1074/JBC.M500806200
P407
P577
2005-09-02T00:00:00Z